<DIV>The biopharmaceutical market is among the most research intensive market sectors globally. Clinical researchers face a multitude of public and private funding options with respect to bringing their idea or innovation to market. These funding options are continually changing and complex, and are expected to decrease in the near future. A lack of understanding of the funding aspects of R&D can, at times, act as a barrier for all involved, and can slow down or even eliminate the R&D process. <BR><BR>Dr. David R. Williams provides a comprehensive critical review of the funding of research and development (R&D) in the human biopharmaceutical market sector. He addresses both private and public funding sources available in the US and internationally The author attempts to lessen these barriers by describing the theoretical underpinnings, present practice, and trends in R&D funding in this market sector. This includes a review and discussion of public private partnership activity and their inner workings, noting the complementary relationship between public and private funding. The book also contains an overview of strategic alliance activity, including the advantages and disadvantages for each party. It goes on to provide an outline of venture capital activity, detailing the methods by which venture capital firms raise capital and are organized, a description of the venture capital entrepreneur arrangement, and the effects of this arrangement and presents an overview of the IPO process and the various fates of firms going public.</div>